Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beloranib in obese subjects with hypothalamic injury
NCT02063295Phase 2Completed
- Sponsor
- Zafgen, Inc.
- Start
- Apr 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Placebo with Beloranib (2 arms). Primary endpoint: Change in body weight at 4 weeks. Started Apr 2014; status: completed.
02
Drugs
beloranib
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02063295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063295.